The Lipid-Lowering Agents market in Burundi has been developing steadily in recent years.
Customer preferences: Burundians are becoming increasingly aware of the importance of managing their cholesterol levels. This has led to a growing demand for Lipid-Lowering Agents, as they are an effective way of reducing cholesterol levels and preventing heart disease. Customers in Burundi are also looking for affordable options, as the cost of healthcare can be a barrier to accessing treatment.
Trends in the market: The Lipid-Lowering Agents market in Burundi has been growing steadily, with an increasing number of people using these drugs to manage their cholesterol levels. There has also been a shift towards generic drugs, as they are more affordable than branded drugs. In addition, there has been an increase in the use of combination therapies, which are more effective at reducing cholesterol levels than single drugs.
Local special circumstances: Burundi is a low-income country, and many people struggle to access healthcare. This has led to a high burden of non-communicable diseases such as heart disease, which can be managed with Lipid-Lowering Agents. However, the cost of these drugs can be a barrier to accessing treatment. In addition, there are limited healthcare resources in Burundi, which can make it difficult for people to access the care they need.
Underlying macroeconomic factors: Burundi is one of the poorest countries in the world, with a GDP per capita of less than $300. This means that many people cannot afford to pay for healthcare out of pocket, and rely on government or donor-funded programs to access treatment. In addition, Burundi has a high burden of communicable diseases such as malaria and HIV, which can divert resources away from non-communicable diseases such as heart disease. Despite these challenges, the Lipid-Lowering Agents market in Burundi is expected to continue growing as more people become aware of the importance of managing their cholesterol levels.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
